-
1
-
-
84875937242
-
Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies
-
Li T, Kung HJ, Mack PC, Gandara DR.Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1039-1049
-
-
Li, T.1
Kung, H.J.2
Mack, P.C.3
Gandara, D.R.4
-
2
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
-
3
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
Maki, R.G.6
-
4
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, openlabel, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
-
5
-
-
84870317500
-
The introduction of systematic genomic testing for patients with nonsmall- cell lung cancer
-
Cardarella S, Ortiz TM, Joshi VA, Butaney M, JackmanDM, Kwiatkowski DJ, et al. The introduction of systematic genomic testing for patients with nonsmall- cell lung cancer. J Thorac Oncol 2012;7:1767-74.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1767-1774
-
-
Cardarella, S.1
Ortiz, T.M.2
Joshi, V.A.3
Butaney, M.4
Jackman, D.M.5
Kwiatkowski, D.J.6
-
6
-
-
84926028427
-
Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): A multicenter, open-label, phase II trial (BRF113928)
-
Planchard D, Kim T, Maziéres J, Quoix E, Riely G, Barlesi F, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928). Ann Oncol 2014;25 (Supplement 5): v1-v41.
-
(2014)
Ann Oncol
, vol.25
, pp. v1-v41
-
-
Planchard, D.1
Kim, T.2
Maziéres, J.3
Quoix, E.4
Riely, G.5
Barlesi, F.6
-
7
-
-
84938274454
-
Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The lung cancer mutation consortium experience
-
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 2015.
-
(2015)
J Thorac Oncol
-
-
Sholl, L.M.1
Aisner, D.L.2
Varella-Garcia, M.3
Berry, L.D.4
Dias-Santagata, D.5
Wistuba, I.I.6
-
8
-
-
84865833740
-
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing
-
Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
-
(2012)
Cancer Discov
, vol.2
, pp. 82-93
-
-
Wagle, N.1
Berger, M.F.2
Davis, M.J.3
Blumenstiel, B.4
Defelice, M.5
Pochanard, P.6
-
9
-
-
84922572706
-
Clinical next-generation sequencing in patients with non-small cell lung cancer
-
Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 2015;121:631-9.
-
(2015)
Cancer
, vol.121
, pp. 631-639
-
-
Hagemann, I.S.1
Devarakonda, S.2
Lockwood, C.M.3
Spencer, D.H.4
Guebert, K.5
Bredemeyer, A.J.6
-
10
-
-
84930699125
-
Realizing the potential of plasma genotyping in an age of genotypedirected therapies
-
Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, et al. Realizing the potential of plasma genotyping in an age of genotypedirected therapies. J Natl Cancer Inst 2014;106(8).
-
(2014)
J Natl Cancer Inst
, vol.106
, Issue.8
-
-
Luke, J.J.1
Oxnard, G.R.2
Paweletz, C.P.3
Camidge, D.R.4
Heymach, J.V.5
Solit, D.B.6
-
11
-
-
84936132730
-
Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: A proof-ofconcept study from BioCAST/IFCT-1002
-
Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-ofconcept study from BioCAST/IFCT-1002. Clin Cancer Res 2014;20: 4613-24.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 4613-4624
-
-
Couraud, S.1
Vaca-Paniagua, F.2
Villar, S.3
Oliver, J.4
Schuster, T.5
Blanché, H.6
-
12
-
-
84655167222
-
Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer
-
Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012;7:115-21.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 115-121
-
-
Goto, K.1
Ichinose, Y.2
Ohe, Y.3
Yamamoto, N.4
Negoro, S.5
Nishio, K.6
-
13
-
-
79960975050
-
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
-
Lee YJ, Yoon KA, Han JY, Kim HT, Yun T, Lee GK, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011;17:5179-87.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5179-5187
-
-
Lee, Y.J.1
Yoon, K.A.2
Han, J.Y.3
Kim, H.T.4
Yun, T.5
Lee, G.K.6
-
14
-
-
84906250256
-
Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumorDNAas a surrogate for determination of EGFR status
-
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumorDNAas a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 1345-1353
-
-
Douillard, J.Y.1
Ostoros, G.2
Cobo, M.3
Ciuleanu, T.4
Cole, R.5
McWalter, G.6
-
15
-
-
84861746437
-
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA
-
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
-
(2012)
Sci Transl Med
, vol.4
, pp. 136ra68
-
-
Forshew, T.1
Murtaza, M.2
Parkinson, C.3
Gale, D.4
Tsui, D.W.5
Kaper, F.6
-
16
-
-
84896539307
-
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
-
Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1698-1705
-
-
Oxnard, G.R.1
Paweletz, C.P.2
Kuang, Y.3
Mach, S.L.4
O'Connell, A.5
Messineo, M.M.6
-
17
-
-
84964198834
-
Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA)
-
Chicago United States
-
Sacher A, Oxnard G, Mach S, Messineo M, Jackman D, Jänne P, et al. Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA). American Society of Clinical Oncology Annual Meeting; Chicago, United States 2014.
-
(2014)
American Society of Clinical Oncology Annual Meeting
-
-
Sacher, A.1
Oxnard, G.2
Mach, S.3
Messineo, M.4
Jackman, D.5
Jänne, P.6
-
18
-
-
84903218109
-
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
-
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
-
(2014)
Nat Med
, vol.20
, pp. 548-554
-
-
Newman, A.M.1
Bratman, S.V.2
To, J.3
Wynne, J.F.4
Eclov, N.C.5
Modlin, L.A.6
-
19
-
-
84964280880
-
-
American Society of Clinical Oncology Annual Meeting; Chicago USA
-
Oxnard G, Lydon C, Lindeman N, Shivdasani P, Chin G, Kuo F, et al. Implementation of clinical next-generation sequencing (NGS) of nonsmall cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration. American Society of Clinical Oncology Annual Meeting; Chicago, USA 2014.
-
(2014)
Implementation of Clinical Next-generation Sequencing (NGS) of Nonsmall Cell Lung Cancer (NSCLC) to Identify EGFR Amplification As A Potentially Targetable Oncogenic Alteration
-
-
Oxnard, G.1
Lydon, C.2
Lindeman, N.3
Shivdasani, P.4
Chin, G.5
Kuo, F.6
-
20
-
-
84928739294
-
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
-
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
-
(2015)
N Engl J Med
, vol.372
, pp. 1689-1699
-
-
Jänne, P.A.1
Yang, J.C.2
Kim, D.W.3
Planchard, D.4
Ohe, Y.5
Ramalingam, S.S.6
-
21
-
-
84930755018
-
Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M
-
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M. Nat Med 2015.
-
(2015)
Nat Med
-
-
Thress, K.S.1
Paweletz, C.P.2
Felip, E.3
Cho, B.C.4
Stetson, D.5
Dougherty, B.6
-
22
-
-
84938196408
-
The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
-
Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015;21:3924-33.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3924-3933
-
-
Niederst, M.J.1
Hu, H.2
Mulvey, H.E.3
Lockerman, E.L.4
Garcia, A.R.5
Piotrowska, Z.6
-
23
-
-
84987849616
-
Acquired resistance of EGFR-mutant lung cancer to a T790M-Specific EGFR inhibitor: Emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain
-
Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-Specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015.
-
(2015)
JAMA Oncol
-
-
Yu, H.A.1
Tian, S.K.2
Drilon, A.E.3
Borsu, L.4
Riely, G.J.5
Arcila, M.E.6
-
24
-
-
84923059431
-
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: A systematic review and meta-analysis
-
Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 2014;4:6269.
-
(2014)
Sci Rep
, vol.4
, pp. 6269
-
-
Luo, J.1
Shen, L.2
Zheng, D.3
-
25
-
-
84907855592
-
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
-
de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251-6.
-
(2014)
Science
, vol.346
, pp. 251-256
-
-
De Bruin, E.C.1
McGranahan, N.2
Mitter, R.3
Salm, M.4
Wedge, D.C.5
Yates, L.6
-
26
-
-
84907808265
-
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
-
Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256-9.
-
(2014)
Science
, vol.346
, pp. 256-259
-
-
Zhang, J.1
Fujimoto, J.2
Wedge, D.C.3
Song, X.4
Seth, S.5
Chow, C.W.6
|